Department of General Surgery, The Third Affiliated Hospital of Soochow University and The First People's Hospital of Changzhou, Changzhou, Jiangsu, China.
J Int Med Res. 2020 Mar;48(3):300060519899780. doi: 10.1177/0300060519899780.
To investigate the prognostic value of pre-treatment serum alpha-fetoprotein (AFP) levels in patients with gastric cancer (GC).
PubMed, EMBASE, Medline and Web of Science databases were systematically searched for studies published between January 01, 1998 and December 31, 2018 that investigated the relationship between pre-treatment serum AFP levels and prognosis of patients with GC. Hazard ratios (HR) for overall survival (OS), disease-free survival (DFS), and their corresponding 95% confidence intervals (CIs) were evaluated.
13 studies involving 9099 patients with GC were included in the meta-analysis. High pre-treatment serum AFP levels were significantly associated with poor outcome in patients with GC. Although there was significant heterogeneity between studies, sub-group analyses found that studies of ‘non-China’ countries, sample size <500, mixed treatment, or AFP cut-off value ≥20 ng/ml, had low heterogeneity.
The pooled analysis suggests that pre-treatment serum AFP levels can be used as a prognostic indicator in patients with GC. Further research is required to confirm these results.
本研究旨在探讨胃癌（GC）患者治疗前血清甲胎蛋白（AFP）水平的预后价值。
系统检索了 1998 年 1 月 1 日至 2018 年 12 月 31 日期间发表的研究，评估了治疗前血清 AFP 水平与 GC 患者总生存（OS）和无病生存（DFS）之间的关系。使用风险比（HR）及其 95%置信区间（CI）评估。
本荟萃分析共纳入了 13 项研究，涉及 9099 例 GC 患者。结果表明，治疗前血清 AFP 水平与 GC 患者的不良预后显著相关。尽管研究之间存在显著异质性，但亚组分析发现，来自“非中国”国家的研究、样本量<500、混合治疗或 AFP 截断值≥20ng/ml 的研究，异质性较低。
本荟萃分析提示，治疗前血清 AFP 水平可作为 GC 患者的预后指标。需要进一步的研究来证实这些结果。
